Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Tianjin Medical University General Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07018375CT.gov The Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Thoracoscopic Lobectomy | — | Not Yet Recruiting | — | — | — |
NCT05718544CT.gov Mini-dose Esketamine-dexmedetomidine Supplemented Analgesia and Long-term Outcomes | — | Completed | — | — | — |
NCT02085577CT.gov The Effect of Intraoperative Ketamine on Opioid Consumption and Pain After Spine Surgery in Opioid-dependent Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Pain Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ondansetron (this asset) | Tianjin Medical University General Hospital | Approved | B · 62 |
| (±)-Tramadol | EMS | P4 | BBB |
| Methadone | Cari Health Inc. | P4 | BBB |
| Lidocaine | National and Kapodistrian University of Athens | P4 | BBB |
| Nepenthe | Bursa City Hospital | P4 | BBB |
| Fentanyl | Aga Khan University | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Stanford University | P4 | BBB |
| Oxycodone | Mayo Clinic | P4 | BBB |
| Buprenorphine | Medical University of South Carolina | P4 | BBB |
+42 more in the Chronic Pain Syndrome cohort
Other indications for Ondansetron
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer Of Unknown Primary Site | — | P3 | BB · 71 |
| Childhood Neoplasm | — | P3 | BB · 66 |
| Alcohol Abuse | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ondansetron in Chronic Pain Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ondansetron-chronic-pain-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →